Accessibility navigation


Use of synthetic CaV2.2 Ca2+ channel peptides to study presynaptic function

Bucci, G., Mochida, S. and Stephens, G. ORCID: https://orcid.org/0000-0002-8966-4238 (2013) Use of synthetic CaV2.2 Ca2+ channel peptides to study presynaptic function. In: Stephens, G. ORCID: https://orcid.org/0000-0002-8966-4238 and Mochida, S. (eds.) Modulation of Presynaptic Calcium Channels. Springer, Dordrecht, pp. 223-240. ISBN 9789400763333

Full text not archived in this repository.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

To link to this item DOI: 10.1007/978-94-007-6334-0

Abstract/Summary

Small, synthetic peptides based on specific regions of voltage-gated Ca2+ channels (VGCCs) have been widely used to study Ca2+ channel function and have been instrumental in confirming the contribution of specific amino acid sequences to interactions with putative binding partners. In particular, peptides based on the Ca2+ channel Alpha Interaction Domain (AID) on the intracellular region connecting domains I and II (the I-II loop) and the SYNaptic PRotein INTerction (synprint) site on the II-III loop have been widely used. Emerging evidence suggests that such peptides may themselves possess inherent functionality, a property that may be exploitable for future drug design. Here, we review our recent work using synthetic Ca2+ channel peptides based on sequences within the CaV2.2 amino terminal and I-II loop, originally identified as molecular determinates for G protein modulation, and their effects on VGCC function. These CaV2.2 peptides act as inhibitory modules to decrease Ca2+ influx with direct effects on VGCC gating, ultimately leading to a reduction of synaptic transmission. CaV2.2 peptides also attenuate G protein modulation of VGCCs. Amino acid substitutions generate CaV2.2 peptides with increased or decreased inhibitory effects suggesting that synthetic peptides can be used to further probe VGCC function and, potentially, form the basis for novel therapeutic development.

Item Type:Book or Report Section
Refereed:Yes
Divisions:Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Division of Pharmacology
ID Code:32683
Publisher:Springer

University Staff: Request a correction | Centaur Editors: Update this record

Page navigation